Acorda Therapeutic bricht aus

Wo geht die Reise hin? Kommt der nächste Ausbruch oder wird der negative Trendkanal weiterverfolgt?

15 Millionen an Lizenzgebühren werden fällig

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that a three-judge arbitration panel has issued a final decision in a dispute with Alkermes PLC (Nasdaq: ALKS) regarding licensing royalties relating to AMPYRA (dalfampridine). Acorda was awarded $15 million plus prejudgment interest of $1.5 million from Alkermes. In addition, as a result of the panel’s ruling, Acorda will no longer have to pay Alkermes any royalties on net sales for license and supply of AMPYRA, and Acorda is now free to use alternative sources for supply of AMPYRA, which the Company has already secured.

“This award will allow Acorda to obtain more competitive market rates for the supply of AMPYRA, significantly reducing our cost of goods and meaningfully increasing the product’s value to the company,” said Ron Cohen, M.D., Acorda’s President and CEO. “This will also help Acorda to continue to provide its customary high level of support for Ampyra, ensuring that as many people with MS as possible may benefit from it.”

Acorda filed an arbitration demand with the American Arbitration Association in July 2020 after the parties were unable to resolve their dispute over license and supply royalties following the 2018 expiration of an Alkermes patent relating to AMPYRA.

ir.acorda.com/investors/investor-news/investor-news-details/2022/­Acorda-Therapeutics-Announces-16.5M-Award-and-RoyaltySupply-Relie­f-in-AMPYRA-Arbitration-Case/default.aspx

ih.advfn.com/stock-market/NASDAQ/...not-use-shares-for-decemb

Geschäftsplan und finanzielle Beratung

finance.yahoo.com/news/...s-provides-long-term-110000118.html

ih.advfn.com/stock-market/NASDAQ/...ts-third-quarter-2022-fin